Allele Communications

Translational Researchers & Biomarker Discovery Professionals! Join me at the upcoming event hosted by Codetta Bio! Gain exclusive insights into their cutting-edge biomarker analysis tool designed to streamline processes and deliver superior outcomes efficiently. This technology eliminates challenges like disparate data and time-consuming analyses on different platforms. Don't miss out on this opportunity to enhance your research capabilities. Sign up now to delve deeper into this innovative solution! #Research #BiomarkerDiscovery #Innovation #Science #Technology #CodettaBio

Are you up to date with the latest in biotech news? Make sure you're signed up to read the full report here: https://loom.ly/XOFx8-c #capitalmarkets #analytics #stocks #biotech #pharma #nasdaq #science #RandD #research

As a pharmaceutical executive, we know how important cost, efficiency, and accuracy are to you. Looking to lower your testing costs by over 60% and utilize an efficient, purpose-built assay for all forms of #NAD and glutathione? Contact us today or visit us at #ADLM this week to order a #NADMED kit and start measuring smarter! Find us at Booth SC-7 in the DxPx Startup City Space. https://loom.ly/QWV7IbA

Are you free on July 15 at 12:30 pm ET (9:30 am PT)? Join Precision BioSciences for its presentation at the JonesTrading Healthcare Seaside Summit! Discover how we have distinguished ourselves as a cutting-edge gene editing company, leveraging our innovative proprietary ARCUS? platform to advance in vivo gene editing therapies. Register today! https://loom.ly/UwrhRSU *A live webcast of the presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at https://lnkd.in/epAiWMAa #GeneEditing #Biotech #DTIL

We're thrilled to announce that the Biomedical Advanced Research and Development Authority (BARDA) has selected Edesa's?first-in-class monoclonal antibody, EB05,?for a U.S. funded platform trial in general Acute Respiratory Distress Syndrome?(ARDS). ? Par Nijhawan, CEO?of?Edesa Biotech, shares his thoughts on the recent announcement and what this means for the Company moving forward.? ? To learn more about Edesa's first-in-class therapies, including EB05, visit https://lnkd.in/g3CqCiUA.? ? #ARDS #Nasdaq

Listen as Par Nijhawan, CEO?of?Edesa Biotech, shares an exciting company update and overview of the upcoming clinical calendar.? ? This is an exciting time for Edesa. Since going public in 2019, the Company has successfully completed two Phase 2 clinical studies and partnered one of these programs with the federal government. Edesa also has two additional Phase 2 assets ready to enter the clinic. ? We believe that?the?positive momentum Edesa has demonstrated since its inception, and the Company’s prudent utilization of cash resources puts us on a solid path to advance our respiratory and dermatology assets, including strategic discussions with potential commercialization and licensing partners. ? For more information, visit edesabiotech.com/ ? #Dermatology #Inflammation #Nasdaq

Want to learn more about how to gain EARLY access to Codetta Bio’s technology? ? Listen as Jacques Corriveau, Codetta Bio CEO, describes what their Technology Access Program (TAP) is and how to get involved.? Additionally, you can also learn more and sign up for this program by visiting:?https://lnkd.in/eRBiVrV3 ? #codetta #multiomics #biomarkers #cytokines #technology

Read the latest press release here: https://loom.ly/ca6Qfqg

Read the our latest press release here: https://lnkd.in/eZQEirxB $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain

Let us reintroduce ourselves– Immuron Limited (ASX: IMC, NASDAQ: IMRN), is a commercial and clinical-stage Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory-mediated and infectious diseases. The Company's commercially available products, Travelan? and Protectyn? are available over-the-counter in three international markets, Australia, Canada, and the USA. To learn more about Immuron and its commercial and clinical stage products, check out our product pipeline https://loom.ly/8MVZdnI! #BioInnovation #FutureOfHealth #GutHealthMatters #DigestiveWellness #ASX #IMC #Nasdaq #IMRN #Travel